195 RIF patients participated in a new independent study.
This independent study concludes that a personalized treatment based on EMMA test recommendations can improve IVF outcomes of patients who have been experiencing recurrent implantation failure.
Besides from the main benefit of improving pregnancy outcomes in patients suffering from recurrent implantation failure by analyzing endometrial microbiome with Igenomix’s EMMA test prior to transfer, two other benefits were identified:
• Broad-spectrum antibiotic treatments can be avoided
EMMA test evaluates the endometrial flora and recommends the best treatment if any alteration is detected.
• The physical and economic burden of patients can be reduced
Dysbiotic endometrial microbiota profiles composed of pathogenic bacteria are associated with unsuccessful outcomes.
The publication, “Therapeutic intervention based on analysis by 16S ribosomal RNA gene sequencing of intrauterine microbiome improves pregnancy outcomes of IVF patients: a prospective cohort study” (Research Square 2022) was led by Dr. Iwami from Kamiya Ladies Clinic in Japan.
Do you want to learn more?
The endometrial flora or microbiome is the sum of the microorganisms and their collective genetic material present in the endometrium
EMMA includes the ALICE test, so it indicates the possible presence of bacteria that can cause chronic endometritis, further other pathogenic bacteria.
What do other studies say?
A previous study shows that endometrial microbiota composition before embryo transfer is an useful biomarker to predict reproductive outcome, offering an opportunity to further improve diagnosis and treatment strategies.
The study, “Endometrial microbiota composition is associated with reproductive outcome in fertilite patients” (Microbiome 2021) was led by Inmaculada Moreno, PhD.
This new publication is a multicenter prospective observational study in a cohort of 342 ethnically diverse infertile patients, asymptomatic for infection undergoing assisted reproductive treatments.